Trusted Partner

The Difference is in the Data

MMS is the data-focused CRO driving pharmaceutical and biotech innovation with unparalleled regulatory expertise and technological innovation. Our experts across four continents are available to support your programs 24 hours a day with an industry-leading Sponsor satisfaction rating.

Full Service Biometrics

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

What Differentiates MMS From Other CROs?

Responsive

MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.

Adaptable

MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.

Focused

MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.

Sponsor feedback
This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.
SVP, Global Regulatory Affairs

AI and Technology

Sponsors can rest assured knowing that MMS will bring new levels of innovation and technology to our processes and deliverables.

KerusCloud®

Don’t roll the dice on your clinical trial

KerusCloud enables pharma and biotech companies to simulate and analyze thousands of virtual trial scenarios optimizing endpoints, recruitment strategies, and overall trial design to improve the probability of trial success.

2006
MMS Founded
in Michigan
950
Loyal
Colleagues
Globally
50
Marketing
Applications in the
Last 5 Years
1
CRO you can
trust

MMS Insights

webinar

August 28th, 2025

Shaping the Future of AI-Enabled  Medical Writing

webinar

July 31st, 2025

Design, Data, and Decisions in Oncology Trials

perspectives

July 29th, 2025

Why Quality by Design Is Still Underused in Emerging Biotech, and What Can Be Done About It